Ivosidenib (IDH1 Inhibitor)
Treatment for Gallbladder And Biliary Tract Cancer
Typical Dosage: 500 mg orally once daily
Effectiveness
40%
Safety Score
45%
Clinical Trials
20
Participants
300
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
500 mg orally once daily
Time to Effect
2-4 months
Treatment Duration
Until progression or unacceptable toxicity (6-18+ months)
Evidence Quality
MODERATEConfidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$270,000
Monitoring:$15,000
Side Effect Mgmt:$5,000
Total Annual:$290,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$900,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$14,500,000
Cost per Remission
$58,000,000
Comparison vs Placebo + Best Supportive Care
Cost Difference
+$280,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Ivosidenib (IDH1 Inhibitor) Outcomes
for Gallbladder And Biliary Tract Cancer
Efficacy Outcomes
Overall Effectiveness
+40%
Response Rate
+2%
Remission Rate
+0.5%
Common Side Effects
Nausea
+35%
Fatigue
+35%
Diarrhea
+30%
Abdominal pain
+25%
QTc prolongation
+12%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov